BNT162b5 [BNT162b5]
topical
- Terms
-
bivalentní vakcína Pfizer-BioNTech proti COVID-19
-
COVID-19 Vaccine Pfizer-BioNTech, Bivalent
Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Persistent link
https://www.medvik.cz/link/D000096106
Definition
A combined mRNA vaccine, developed by Pfizer and BioNTech against SARS-CoV-2 with a mixture of the original strain of SARS-CoV-2 and BA.4 and BA.5 lineages of the omicron variant of SARS-CoV-2.
- DUI
- D000096106 MeSH Browser
- CUI
- M000759679
- History note
- 2024
- Public note
- 2024
Allowable subheadings
- AD
- administration & dosage
- AE
- adverse effects
- AG
- agonists
- AA
- analogs & derivatives
- AN
- analysis
- AI
- antagonists & inhibitors
- BI
- biosynthesis
- BL
- blood
- CF
- cerebrospinal fluid
- CS
- chemical synthesis
- CH
- chemistry
- CL
- classification
- EC
- economics
- GE
- genetics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics
- PD
- pharmacology
- PO
- poisoning
- RE
- radiation effects
- ST
- standards
- SD
- supply & distribution
- TU
- therapeutic use
- TO
- toxicity
- UR
- urine
...
Occurrences in Medvik records
D
Chemicals and Drugs
D12.776.828.868.228
Nucleic Acid-Based Vaccines
D12.776.828.868.228.500.875
BNT162b5
D20.215.894.815.750
BNT162b5
D20.215.894.865.450
Nucleic Acid-Based Vaccines
D20.215.894.865.450.500.875
BNT162b5
D20.215.894.899.085.750
BNT162b5
D23.050.865.450
Nucleic Acid-Based Vaccines
D23.050.865.450.500.875
BNT162b5